Proof of Concept (Bone Resorption/Bone Mineral Density) Study (0429-005)
Phase 2
Completed
- Conditions
- Post-Menopausal Osteoporosis
- Registration Number
- NCT00533650
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Brief Summary
A study to asses the safety and efficacy of MK0429 in postmenopausal women with osteoporosis.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 227
Inclusion Criteria
- Person is a women with osteoporosis who is unwilling or unable to take other treatments for osteoporosis
Exclusion Criteria
- Person has had a previous fracture
- Person has rheumatoid arthritis. Person has has certain types of cancer
- Person has donated blood or has been in another investigational study within the last 4 weeks
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does MK0429 target to inhibit bone resorption in postmenopausal osteoporosis?
How does MK0429 compare to bisphosphonates in improving bone mineral density in postmenopausal women?
What biomarkers were used in NCT00533650 to assess efficacy and patient response in osteoporosis treatment?
What adverse events were reported in the phase 2 trial of MK0429 for postmenopausal osteoporosis?
Are there combination therapies involving MK0429 that enhance bone mineral density outcomes in osteoporotic patients?